227
Participants
Start Date
June 9, 2016
Primary Completion Date
August 28, 2020
Study Completion Date
August 28, 2020
Enzalutamide
Oral
Active Surveillance
Site US10068, Brooklyn
Site US10030, Garden City
Site US10028, Poughkeepsie
Site US10021, Syracuse
Site US10022, Syracuse
Site US10050, Cheektowaga
Site US10052, Lancaster
Site US10063, Bala-Cynwyd
Site US10001, Towson
Site US10058, Richmond
Site US10047, Gastonia
Site US10019, Myrtle Beach
Site US10057, Lakeland
Site US10072, Bradenton
Site US10024, Homewood
Site US10034, Birmingham
Site US10011, Nashville
Site US10015, Middleburg Heights
Site US10045, Cleveland
Site US10046, Carmel
Site US10009, Jeffersonville
Site US10008, Troy
Site US10017, Milwaukee
Site US10071, Lake Barrington
Site US10018, Glenview
Site US10038, Chicago
Site US10062, Chicago
Site US10074, Chicago
Site US10044, Omaha
Site US10067, Omaha
Site US10069, Lincoln
Site US10037, New Orleans
Site US10006, Shreveport
Site US10053, Oklahoma City
Site US10056, Dallas
Site US10036, Houston
Site US10035, San Antonio
Site US10051, Aurora
Site US10029, Denver
Site US10054, Denver
Site US10007, Tucson
Site US10055, Tucson
Site US10004, Los Angeles
Site US10010, San Diego
Site US10026, Sacramento
Site US10032, Boston
Site US10061, Lebanon
Site US10049, Morristown
Site US10043, Voorhees Township
Site US10014, Warwick
Site CA15005, Abbotsford
Site CA15004, Halifax
Site CA15001, Toronto
Site CA15003, Toronto
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY